Streptokinase-Streptodornase （Varidase口服錠）的臨床使用經驗

Clinical Experience of Oral Streptokinase-Streptodornase

張榮茂(Jung-Mao Chang) ； 楊燕飛(Yen-Fei Yang) ； 柯良時(Liang-Shi Ko)

《中華民國眼科醫學會會刊》 5卷 (1966/05) Pp. 60-67

https://doi.org/10.30048/ACTASOS.196605.0009

並列摘要

Since the introduction of systemic therapy of streptokinase-streptodornase in 1955, it was reported that the administration of this drug is justified as an adjuvant in the treatment of hemorrhagic conditions and inflammatory processes of the eye such as subconjunctival hemorrhage, hyphema, vitreous hemorrhage, retinal vein thrombosis, retinopathy, edema of the lids and conjunctiva, iridocyclitis, central retinopathy, and commotio retinae etc.
The fibrinolytic enzyme in the blood is called fibrinolysin (plasmin), which is obtainable by activation of the inactive precursor profibrinolysin. Profibrinolysin is capable of activation by a number of substances, activator, found in the human tissues and secretions. An enzyme streptokinase react with a proactivator to form an activator capable of converting profibrinolysin to proteolytic enzrme fibrinolysin. Fibrinolysin appears to hydrolyze fibrin which results from coagulation of fibrinogen. With the advent of streptokinase, the attempt to remove chemically an occluding clot has become feasible.
The purpose of this study is to see the proteolytic effect of streptokinase on ocular diseases, mainly hemorragic conditions. Varidase oral tablet (contains 10,000 units streptokinase and 2,500 units streptodornase in each tablet), developed by Leaderle Lab.) was used (1 tab. q. i. d.) for a period of 5 days to over one month long.
In 38 cases the drug was given, while 21 cases were taken as control group without Varidase administration. Both groups were put under close observation.
The results were illustrated in the following table.
Ⅰ. Effect on hyphema
(The form abridges)
Ⅱ. Effect on retinal hemorrhage
(The form abridges)
Ⅲ. Effect on retinal vein thrombosis
(The form abridges)
Varidase was tolerated by all patients ertremely well without any noticeable side effects even in cases in which the drug was administered for more than one month.
Any estimation of drug efficacy is difficult. The results obtained in the groups of patients of hyphema, retinal hemorrhage, vitreous hemorrhage and retinal venous thrombosis given oral Varidase were definitely better than those of the control groups. Nevertheless these differences between the groups of oral Varidase and control are insignificant statistically. Our trial cases are not large in number. The effectiveness of oral Varidase as fibrinolytic agent is not yet definitely proven. However, from this clinical experiment we may conisider that it is a possibility that such therapy will be beneficial in hemorrhagic disorders of the eye. The authors agree with the opinion of the other investigators that oral streptokinase (Varidase) may be administered as an adjuvant in the treatment of the hemorrhagic conditions of the eye.